AbCellera Biologics Inc. (NASDAQ:ABCL) is Intellectus Partners LLC’s 10th Largest Position

Intellectus Partners LLC lifted its stake in AbCellera Biologics Inc. (NASDAQ:ABCL) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 887,283 shares of the company’s stock after purchasing an additional 10,650 shares during the quarter. AbCellera Biologics comprises 1.5% of Intellectus Partners LLC’s portfolio, making the stock its 10th biggest holding. Intellectus Partners LLC’s holdings in AbCellera Biologics were worth $5,066,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of ABCL. Trexquant Investment LP boosted its holdings in AbCellera Biologics by 458.5% during the 3rd quarter. Trexquant Investment LP now owns 272,158 shares of the company’s stock valued at $1,252,000 after acquiring an additional 223,430 shares during the period. Schonfeld Strategic Advisors LLC raised its position in AbCellera Biologics by 143.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 358,400 shares of the company’s stock valued at $1,649,000 after purchasing an additional 211,000 shares in the last quarter. Dark Forest Capital Management LP raised its position in AbCellera Biologics by 199.6% during the 3rd quarter. Dark Forest Capital Management LP now owns 278,618 shares of the company’s stock valued at $1,282,000 after purchasing an additional 185,606 shares in the last quarter. GSA Capital Partners LLP raised its position in AbCellera Biologics by 1,268.1% during the 3rd quarter. GSA Capital Partners LLP now owns 146,190 shares of the company’s stock valued at $672,000 after purchasing an additional 135,504 shares in the last quarter. Finally, Graham Capital Management L.P. raised its position in AbCellera Biologics by 149.4% during the 3rd quarter. Graham Capital Management L.P. now owns 180,389 shares of the company’s stock valued at $830,000 after purchasing an additional 108,060 shares in the last quarter. Hedge funds and other institutional investors own 61.42% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on ABCL shares. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 price target for the company in a research report on Thursday, February 22nd. Stifel Nicolaus reduced their price target on AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 21st. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $15.86.

AbCellera Biologics Trading Up 3.6 %

AbCellera Biologics stock traded up $0.13 during mid-day trading on Friday, hitting $3.76. The company’s stock had a trading volume of 1,369,561 shares, compared to its average volume of 1,075,373. AbCellera Biologics Inc. has a 1 year low of $3.62 and a 1 year high of $8.05. The stock’s fifty day moving average is $4.56 and its two-hundred day moving average is $4.80.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings data on Tuesday, February 20th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03). AbCellera Biologics had a negative return on equity of 12.36% and a negative net margin of 384.99%. The business had revenue of $9.18 million during the quarter, compared to analysts’ expectations of $9.58 million. As a group, research analysts predict that AbCellera Biologics Inc. will post -0.66 earnings per share for the current year.

AbCellera Biologics Company Profile

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.